Menu
Back to User profile » Dr Robert Fogel
Papers published by Dr Robert Fogel:
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database [Corrigendum]
Kostikas K, Price D, Gutzwiller FS, Jones B, Loefroth E, Clemens A, Fogel R, Jones R, Cao H
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:2559-2560
Published Date: 16 October 2020
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database
Kostikas K, Price D, Gutzwiller FS, Jones B, Loefroth E, Clemens A, Fogel R, Jones R, Cao H
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:1729-1738
Published Date: 16 July 2020
Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study
Kostikas K, Rhee CK, Hurst JR, Agostoni P, Cao H, Fogel R, Jones R, Kocks JWH, Mezzi K, Wan Yau Ming S, Ryan R, Price DB
Pragmatic and Observational Research 2020, 11:55-66
Published Date: 2 June 2020
Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:853-861
Published Date: 16 April 2019
Gender-specific estimates of COPD prevalence: a systematic review and meta-analysis
Ntritsos G, Franek J, Belbasis L, Christou MA, Markozannes G, Altman P, Fogel R, Sayre T, Ntzani EE, Evangelou E
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1507-1514
Published Date: 10 May 2018
Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study
Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1229-1237
Published Date: 16 April 2018
Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study
Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:1125-1134
Published Date: 10 April 2018
The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1325-1337
Published Date: 4 May 2017
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:907-922
Published Date: 17 March 2017
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study
Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:339-349
Published Date: 19 January 2017
Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
Vogelmeier C, Zhong NS, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:3189-3197
Published Date: 14 December 2016